Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06292598

Bacterial Translocation and Gut Microbiota in Type 1 Narcolepsy Patients Versus a Control Population

Narcolepsy type 1 (NT1) is a rare disease characterized by severe drowsiness, cataplexy, hypnagogic hallucinations, sleep paralysis, poor night sleep, and often obesity. NT1 is caused by irreversible loss of orexin (ORX)/hypocretin neurons in the lateral hypothalamus with decreased ORX levels in the cerebrospinal fluid (CSF). Although the underlying process leading to this destruction remains unclear; an autoimmune origin is suspected.

The study authors recently compared the bacterial communities of the fecal microbiota of NT1 patients and control subjects. Initial results demonstrated a difference in overall bacterial community structure in NT1 compared to controls, as assessed by beta diversity, even after adjusting for body mass index (BMI). The Shannon biodiversity index was also correlated with the duration of NT1 disease. However, no association was found between the structure of the microbial community and the clinical characteristics of NT1 patients.

In 2022, a second study from the SOMNOBANK cohort on a larger population confirmed these results, showing dysbiosis between NT1 patients and the control population. The altered intestinal microbial diversity supports the important role of the environment in the development and pathogenesis of NT1. Other studies have established a link between dysbiosis, intestinal permeability and inflammation in other neuroimmune pathologies. Currently, no study has focused on these phenomena of bacterial translocation, intestinal permeability and immune activation linked to the microbiota in type 1 narcolepsy patients.

The study hypothesis is that NT1 patients with dysbiosis in their intestinal microbiota also present a bacterial translocation with an intestinal origin, leading to a systemic inflammatory syndrome favoring an autoimmune damage destroying hypocretin neurons in the hypothalamus. The study authors suspect that microbial elements (DNA) involved in the autoimmune process could be detected in the CSF. This bacterial translocation could vary over time depending on: i) the progression of the disease and its management; ii) changing dysbiosis and: iii) the increase in intestinal permeability and inflammation.

Recruiting

Interested in participating?

Request Info

Key information

Age range

10 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Nîmes University Hospital, Nîmes, Gard, France

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient diagnosed with narcolepsy type 1 (NT1).
  • Patient not treated for narcolepsy during initial evaluation of NT1 patients.
  • Patient eligible for treatment for longitudinal monitoring of NT1 patients.
  • Patient speaking and understanding French.
  • The patient must have given their free and informed consent and signed the consent form or consent has been provided from the holder(s) of parental authority or the legal guardian and the child.
  • The patient must be a member or beneficiary of a health insurance plan

Inclusion criteria

for control subjects:

  • Absence of diagnosis of sleep disorder responsible for hypersomnolence with an Epworth sleepiness scale score greater than 10/24.

Exclusion criteria

  • Subject having presented an infectious pathology requiring antibiotic treatment in the previous 3 months.
  • Subject with a dysimmune pathology.
  • Subject having had treatment with an immunomodulatory molecule or chemotherapy within 60 days before inclusion in the research or whose indication is planned for the duration of the research.
  • Subject with a chronic digestive pathology or having undergone bariatric surgery in the previous year.
  • Subject on laxative.
  • Subject living in a medical institution.
  • Subject under legal protection, guardianship or curatorship.
  • Subject and/or their legal representative (if a minor patient) unable to express consent
  • Taking antibiotics during the inclusion period, or laxative or any other treatment having a significant impact on the microbiota

Treatment and study plan

blood sample

Other

Sample taken to test plasma permeability markers

Stool sample

Other

Sample taken to test microbial diversity and composition

CSF sample

Other

Sample taken to test orexin level

Primary outcomes

  1. Plasma bacterial translocation profiles between groups

    Time frame: Day 0

    Circulating plasma r16s DNA (copies/μL)

Secondary outcomes

  1. Plasma bacterial translocation profiles in NT1 patients

    Time frame: Month 12

    Circulating plasma r16s DNA (copies/μL)

  2. Taxonomic characteristics of DNA in the CSF of NT1 patients according to narcolepsy severity

    Time frame: Day 0

    Metagenomic sequencing of all genomes present, compared with international databases, presented as number of reads per species (bacterial, fungal and viral)

  3. Taxonomic characteristics of plasma bacterial DNA in patients with high bacterial translocation

    Time frame: Day 0

    Metabarcoding of 16srDNA of bacterial DNA present in plasma in NT1 patients with 16S rDNA >25 copies/μL, presented as relative abundance of bacterial phyla and genera (%)

  4. Taxonomic characteristics of plasma bacterial DNA in patients with high bacterial translocation

    Time frame: Month 12

    Metabarcoding of 16srDNA of bacterial DNA present in plasma in NT1 patients with 16S rDNA >25 copies/μL, presented as relative abundance of bacterial phyla and genera (%)

  5. Beta diversity of the intestinal microbiota between groups

    Time frame: Day 0

    measured by metabarcoding

  6. Beta diversity of the intestinal microbiota in NT1 patients

    Time frame: Month 12

    measured by metabarcoding

  7. Alpha diversity of the intestinal microbiota between groups

    Time frame: Day 0

    measured by metabarcoding

  8. Alpha diversity of the intestinal microbiota in NT1 patients

    Time frame: Month 12

    measured by metabarcoding

  9. Composition of the intestinal microbiota between groups

    Time frame: Day 0

    Relative abundance of bacterial phyla and genera (%) measured by metabarcoding

  10. Composition of the intestinal microbiota between groups

    Time frame: Month 12

    Relative abundance of bacterial phyla and genera (%) measured by metabarcoding

  11. Plasma Intestinal Fatty Acid Binding Protein (i-FABP) profile between groups

    Time frame: Day 0

    Measured by ELISA (pg/mL)

  12. Plasma Intestinal Fatty Acid Binding Protein (i-FABP) profile in NT1 patients

    Time frame: Month 12

    Measured by ELISA (pg/mL)

  13. Plasma LPS-binding Protein (LBP) profile between groups

    Time frame: Day 0

    Measured by ELISA (μg/mL

  14. Plasma LPS-binding Protein (LBP) profile in NT1 patients

    Time frame: Month 12

    Measured by ELISA (μg/mL

  15. Plasma Soluble CD14 profile between groups

    Time frame: Day 0

    Measured by ELISA (μg/mL

  16. Plasma Soluble CD14 profile in NT1 patients

    Time frame: Month 12

    Measured by ELISA (μg/mL

  17. Age of onset of symptoms in NT1 patients

    Time frame: Day 0

    Years

  18. Duration of disease progression in NT1 patients

    Time frame: Day 0

    Years

  19. Severity of sleep-related symptoms in NT1 patients

    Time frame: Day 0

    Epworth scale

  20. Severity of narcolepsy symptoms in NT1 patients

    Time frame: Day 0

    Narcolepsy Severity Scale

  21. Description of comorbidities in NT1 patients

    Time frame: Day 0

    List

  22. Sleep onset latency in NT1 patients

    Time frame: Day 0

    Minutes

  23. Number of rapid eye movement sleep episodes in NT1 patients

    Time frame: Day 0

    Number

  24. Orexin levels in CSF in NT1 patients

    Time frame: Day 0

    Measured by Radio-immuno-assay (pg/ml)

Study contacts

Contact information is provided by the study sponsor or research team.

Catherine Dunyach-Remy

CONTACT

[email protected]

0466683202

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire de Nīmes

Other

Registry information

Official study title

Bacterial Translocation and Gut Microbiota in Type 1 Narcolepsy Patients

Acronym: NARCOBIOTE

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Mar 5, 2024
Registry last updated
Nov 17, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.